Cargando…

Survival after heart transplantation for non-metastatic primary cardiac sarcoma

BACKGROUND: Heart transplantation is an uncommon treatment for unresectable and non-metastatic primary cardiac sarcomas, and the role of it is unclear. This study aims to offer a survival analysis of it. METHODS: This study consists of 6 patients from our institution and 40 patients identified in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hua, Yang, Shouguo, Chen, Hao, Yang, Zhaohua, Hong, Tao, Hou, Yingyong, Wang, Chunsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048623/
https://www.ncbi.nlm.nih.gov/pubmed/27716444
http://dx.doi.org/10.1186/s13019-016-0540-x
_version_ 1782457604617797632
author Li, Hua
Yang, Shouguo
Chen, Hao
Yang, Zhaohua
Hong, Tao
Hou, Yingyong
Wang, Chunsheng
author_facet Li, Hua
Yang, Shouguo
Chen, Hao
Yang, Zhaohua
Hong, Tao
Hou, Yingyong
Wang, Chunsheng
author_sort Li, Hua
collection PubMed
description BACKGROUND: Heart transplantation is an uncommon treatment for unresectable and non-metastatic primary cardiac sarcomas, and the role of it is unclear. This study aims to offer a survival analysis of it. METHODS: This study consists of 6 patients from our institution and 40 patients identified in a literature search who underwent heart transplantation for non-metastatic primary cardiac sarcomas. Seven patients with unresectable cardiac angiosarcoma who received palliative therapies at our institution were included for comparison. All the clinicopathologic data were collected, retrospectively reviewed and statistically analyzed. RESULTS: Among the 46 patients receiving heart transplantation for primary cardiac sarcomas, the overall median survival was 16 months (2–112 months). The most common histologic type receiving heart transplantation was angiosarcoma. Its median survival time after heart transplantation (n = 14) was much less than that of other histologic types (n = 31) (9 vs 36 months; P = 0.002), which means it was not different from the median survival of 8 months for patients (n = 7) receiving palliative therapies (P = 0.768). The patients with grade 2 cardiac sarcomas (n = 5) survived much longer after heart transplantations than patients with grade 3 tumors (n = 15) (mean survival: 85 vs 18 months; P = 0.006). Neoadjuvant or adjuvant chemotherapy didn’t provide survival benefits after heart transplantation. CONCLUSIONS: Cardiac angiosarcoma seems to be not the proper indication of heart transplantation. The role of heart transplantation in other histologic subtypes still remains undefined. Lower grade and less aggressive histologic subtypes benefit more from heart transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13019-016-0540-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5048623
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50486232016-10-11 Survival after heart transplantation for non-metastatic primary cardiac sarcoma Li, Hua Yang, Shouguo Chen, Hao Yang, Zhaohua Hong, Tao Hou, Yingyong Wang, Chunsheng J Cardiothorac Surg Research Article BACKGROUND: Heart transplantation is an uncommon treatment for unresectable and non-metastatic primary cardiac sarcomas, and the role of it is unclear. This study aims to offer a survival analysis of it. METHODS: This study consists of 6 patients from our institution and 40 patients identified in a literature search who underwent heart transplantation for non-metastatic primary cardiac sarcomas. Seven patients with unresectable cardiac angiosarcoma who received palliative therapies at our institution were included for comparison. All the clinicopathologic data were collected, retrospectively reviewed and statistically analyzed. RESULTS: Among the 46 patients receiving heart transplantation for primary cardiac sarcomas, the overall median survival was 16 months (2–112 months). The most common histologic type receiving heart transplantation was angiosarcoma. Its median survival time after heart transplantation (n = 14) was much less than that of other histologic types (n = 31) (9 vs 36 months; P = 0.002), which means it was not different from the median survival of 8 months for patients (n = 7) receiving palliative therapies (P = 0.768). The patients with grade 2 cardiac sarcomas (n = 5) survived much longer after heart transplantations than patients with grade 3 tumors (n = 15) (mean survival: 85 vs 18 months; P = 0.006). Neoadjuvant or adjuvant chemotherapy didn’t provide survival benefits after heart transplantation. CONCLUSIONS: Cardiac angiosarcoma seems to be not the proper indication of heart transplantation. The role of heart transplantation in other histologic subtypes still remains undefined. Lower grade and less aggressive histologic subtypes benefit more from heart transplantation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13019-016-0540-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-03 /pmc/articles/PMC5048623/ /pubmed/27716444 http://dx.doi.org/10.1186/s13019-016-0540-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Hua
Yang, Shouguo
Chen, Hao
Yang, Zhaohua
Hong, Tao
Hou, Yingyong
Wang, Chunsheng
Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title_full Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title_fullStr Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title_full_unstemmed Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title_short Survival after heart transplantation for non-metastatic primary cardiac sarcoma
title_sort survival after heart transplantation for non-metastatic primary cardiac sarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048623/
https://www.ncbi.nlm.nih.gov/pubmed/27716444
http://dx.doi.org/10.1186/s13019-016-0540-x
work_keys_str_mv AT lihua survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT yangshouguo survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT chenhao survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT yangzhaohua survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT hongtao survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT houyingyong survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma
AT wangchunsheng survivalafterhearttransplantationfornonmetastaticprimarycardiacsarcoma